Acrux (ASX:ACR) Short Percentage of Float

View and export this data going back to 2004. Start your Free Trial

What is Acrux Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Acrux's Short Percentage of Float

For the Biotechnology subindustry, Acrux's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acrux's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Acrux's Short Percentage of Float falls into.

Acrux (ASX:ACR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

ARUXF:USA FJY:Germany

Address

103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003

Website

https://www.acrux.com.au

Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.